BLUE
Bluebird bio Inc
Halal Rating :
Last Price
$8.35
Last updated:
Market Cap
-
7D Change
-1.65%
1 Year Change
557.48%
Company Overview
Industries
Exchange
Next Earnings Date
bluebird bio, Inc. is a biotechnology company focused on developing gene therapies for severe genetic diseases and cancer. The company specializes in developing treatments using a patient's own genetically modified cells to treat various conditions. Their primary focus is on developing treatments for rare genetic diseases and certain types of cancer.
The company has developed several gene therapy products including ZYNTEGLO for beta-thalassemia, SKYSONA for cerebral adrenoleukodystrophy (CALD), and LYFGENIA for sickle cell disease.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $10.61m | $83.31m | - | $5.78m | 0.00% | 6.94% |
| June 30, 2024 | $16.1m | $109.95m | - | $5.45m | 0.00% | 4.96% |
| March 31, 2024 | $18.57m | $102.12m | - | $4.86m | 0.00% | 4.76% |
Company Impact
Help us evaluate Bluebird bio Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.